| HOME >> BIOLOGY >> TECHNOLOGY |
Timothy L. Enns
SVP, Corporate Communications & Business Development
Tel: (925) 560-0100
E-mail: tenns@supergen.com
Mary M. Vegh
Manager, Investor Relations
Tel: (925) 560-2845
E-mail: mary.vegh@supergen.com
Dorland Global Public Relations
Michael Beckerich (Media)
Tel: (212) 677-7632
E-mail: mbeckerich@dorland.com
Condensed Consolidated Statements of Operations and Balance Sheets to
follow...
SUPERGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
Revenues:
Net product revenue $- $- $- $621
Royalty revenue 10,209 6,123 26,480 14,536
Total revenues 10,209 6,123 26,480 15,157
Costs and operating expenses:
Cost of product revenue - - - 221
Research and development 8,841 6,170 24,528 17,185
Selling, general, and
administrative 2,511 3,072 8,860 10,345
Acquired in-process research
and development - - - 9,967
Gain on sale of products - (1,828) (1,560) (27,677)
Total costs and operating
expenses 11,352 7,414 31,828 10,041
Income (loss) from operations
'/>"/>
| SOURCE SuperGen, Inc. Copyright©2008 PR Newswire. All rights reserved |